ARTICLE | Clinical News
MOB-015: Interim Phase II data
January 27, 2014 8:00 AM UTC
Interim data from an open-label, Swedish Phase II trial in 25 patients with onychomycosis showed that once-daily topical MOB-015 led to mycological cure of the target nail, defined as negative fungal ...